Benchmark Downgrades CryoLife (CRY) to Hold

August 6, 2012 7:25 AM EDT Send to a Friend
Get Alerts CRY Hot Sheet
Price: $10.28 -0.87%

Rating Summary:
    2 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 31 | New: 28
Trade CRY Now!
Join SI Premium – FREE
Benchmark downgraded CryoLife (NYSE: CRY) from Buy to Hold with a price target of $6.00 (from $7.50).

Analyst Raymond Myers said "We are lowering our rating to Hold following Q2 results as PerClot’s FDA clinical trial enrollment was delayed from mid-2012 to early 2013. We believe this shift is benefiting 2012 results through lower R&D expenditure, at the expense of 2013. We now forecast meaningful earnings expansion beginning in 2014. Our lowered $6.00 price target is 20x $0.37 EPS in 2014, discounted one year at 25%, plus $0.34 per share in cash."

For an analyst ratings summary and ratings history on CryoLife click here. For more ratings news on CryoLife click here.

Shares of CryoLife closed at $5.21 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment